297 related articles for article (PubMed ID: 29096627)
21. Safety and Efficacy of Revefenacin and Formoterol in Sequence and Combination via a Standard Jet Nebulizer in Patients with Chronic Obstructive Pulmonary Disease: A Phase 3b, Randomized, 42-Day Study.
Siler TM; Moran EJ; Barnes CN; Crater GD
Chronic Obstr Pulm Dis; 2020 Apr; 7(2):99-106. PubMed ID: 32324981
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease.
Ichinose M; Takizawa A; Izumoto T; Tadayasu Y; Hamilton AL; Kunz C; Fukuchi Y
Int J Chron Obstruct Pulmon Dis; 2015; 10():1673-83. PubMed ID: 26316741
[TBL] [Abstract][Full Text] [Related]
23. Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease.
Hvisdas C
Am J Health Syst Pharm; 2021 Jun; 78(13):1184-1194. PubMed ID: 33821890
[TBL] [Abstract][Full Text] [Related]
24. Revefenacin for the treatment of chronic obstructive pulmonary disease.
Li F; Yang J
Expert Rev Clin Pharmacol; 2019 Apr; 12(4):293-298. PubMed ID: 30803279
[TBL] [Abstract][Full Text] [Related]
25. Safety evaluation of revefenacin at the approved dose in patients with chronic obstructive pulmonary disease: A meta-analysis.
Liu B; Zan S; Luo W
Heart Lung; 2022; 52():52-60. PubMed ID: 34875569
[TBL] [Abstract][Full Text] [Related]
26. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
Hohlfeld JM; Vogel-Claussen J; Biller H; Berliner D; Berschneider K; Tillmann HC; Hiltl S; Bauersachs J; Welte T
Lancet Respir Med; 2018 May; 6(5):368-378. PubMed ID: 29477448
[TBL] [Abstract][Full Text] [Related]
27. A novel model-based approach for dose determination of glycopyrronium bromide in COPD.
Arievich H; Overend T; Renard D; Gibbs M; Alagappan V; Looby M; Banerji D
BMC Pulm Med; 2012 Dec; 12():74. PubMed ID: 23217058
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
Franciosi LG; Diamant Z; Banner KH; Zuiker R; Morelli N; Kamerling IM; de Kam ML; Burggraaf J; Cohen AF; Cazzola M; Calzetta L; Singh D; Spina D; Walker MJ; Page CP
Lancet Respir Med; 2013 Nov; 1(9):714-27. PubMed ID: 24429275
[TBL] [Abstract][Full Text] [Related]
29. Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials.
Donohue JF; Feldman G; Sethi S; Barnes CN; Pendyala S; Bourdet D; Crater G
Pulm Pharmacol Ther; 2019 Aug; 57():101808. PubMed ID: 31152911
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of the long-acting muscarinic antagonist GSK233705 delivered once daily in patients with COPD.
Bateman E; Feldman G; Kilbride S; Brooks J; Mehta R; Harris S; Maden C; Crater G
Clin Respir J; 2012 Oct; 6(4):248-57. PubMed ID: 22329914
[TBL] [Abstract][Full Text] [Related]
31. Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study.
Church A; Beerahee M; Brooks J; Mehta R; Shah P
BMC Pulm Med; 2014 Jan; 14():2. PubMed ID: 24393134
[TBL] [Abstract][Full Text] [Related]
32. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients.
Verkindre C; Fukuchi Y; Flémale A; Takeda A; Overend T; Prasad N; Dolker M
Respir Med; 2010 Oct; 104(10):1482-9. PubMed ID: 20541381
[TBL] [Abstract][Full Text] [Related]
33. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4.
Ohar J; Tosiello R; Goodin T; Sanjar S
Int J Chron Obstruct Pulmon Dis; 2019; 14():27-37. PubMed ID: 30587959
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
Dahl R; Chapman KR; Rudolf M; Mehta R; Kho P; Alagappan VK; Chen H; Banerji D
Respir Med; 2013 Oct; 107(10):1558-67. PubMed ID: 23867808
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease.
Leaker BR; Barnes PJ; Jones CR; Tutuncu A; Singh D
Br J Clin Pharmacol; 2015 Mar; 79(3):492-500. PubMed ID: 25243340
[TBL] [Abstract][Full Text] [Related]
37. Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow Rate.
Mahler DA; Ohar JA; Barnes CN; Moran EJ; Pendyala S; Crater GD
Chronic Obstr Pulm Dis; 2019 Oct; 6(4):321-31. PubMed ID: 31647854
[TBL] [Abstract][Full Text] [Related]
38. A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting β2-adrenergic agonist, in asthma; a Phase II, randomized study.
Singh D; Pujol H; Ribera A; Seoane B; Massana E; Astbury C; Ruiz S; de Miquel G
BMC Pulm Med; 2014 Nov; 14():176. PubMed ID: 25398689
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.
Fuhr R; Magnussen H; Sarem K; Llovera AR; Kirsten AM; Falqués M; Caracta CF; Garcia Gil E
Chest; 2012 Mar; 141(3):745-752. PubMed ID: 21903737
[TBL] [Abstract][Full Text] [Related]
40. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
Mahler DA; Gifford AH; Satti A; Jessop N; Eckert JH; D'Andrea P; Mota F; Banerjee R
Respir Med; 2016 Jun; 115():39-45. PubMed ID: 27215502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
